30 likes | 179 Views
APPRAISE. ISTH major or CRNM bleeding: 7.9% for 10 mg apixaban, 5.7% for 5 mg apixaban, 3% for placebo Death, MI, recurrent ischemia, or stroke: 6.0%, 7.6%, 8.7% (p = 0.07 for high dose vs. placebo and p = 0.21 for low dose vs. placebo), respectively.
E N D
APPRAISE ISTH major or CRNM bleeding: 7.9% for 10 mg apixaban, 5.7% for 5 mg apixaban, 3% for placebo Death, MI, recurrent ischemia, or stroke: 6.0%, 7.6%, 8.7% (p = 0.07 for high dose vs. placebo and p = 0.21 for low dose vs. placebo), respectively Trial design:Patients recovering from an ACS were randomized to apixaban 10 mg daily (n = 318), apixaban 2.5 mg twice daily (n = 317), or placebo (n = 611). Study medications were administered for 6 months. Results (p = 0.005 for high dose vs. placebo) (p = 0.09 for low dose vs. placebo) 7.9 5.7 % Conclusions 3.0 • This dose-finding study reveals that bleeding is increased among patients with a recent ACS with higher doses of apixaban compared with placebo • Although this study was not powered for efficacy, adverse events appeared to be lowest with 10 mg apixaban ISTH major or CRNM bleeding Apixaban 10 mg Apixaban 5 mg Placebo APPRAISE Investigators. Circulation 2009;May 26:[Epub]